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OBJECTIVES: This study was conducted to determine whether the blood pressure-lowering effect of Nigella
sativa might be mediated by its effects on nitric oxide, angiotensin-converting enzyme, heme oxygenase and
oxidative stress markers.
METHODS: Twenty-four adult male Sprague-Dawley rats were divided equally into 4 groups. One group served
as the control (group 1), whereas the other three groups (groups 2-4) were administered L-NAME (25 mg/kg,
intraperitoneally). Groups 3 and 4 were given oral nicardipine daily at a dose of 3 mg/kg and Nigella sativa oil at
a dose of 2.5 mg/kg for 8 weeks, respectively, concomitantly with L-NAME administration.
RESULTS : Nigella sativa oil prevented the increase in systolic blood pressure in the L-NAME-treated rats. The
blood pressure reduction was associated with a reduction in cardiac lipid peroxidation product, NADPH oxidase,
angiotensin-converting enzyme activity and plasma nitric oxide, as well as with an increase in heme oxygenase-1
activity in the heart. The effects of Nigella sativa on blood pressure, lipid peroxidation product, nicotinamide
adenine dinucleotide phosphate oxidase and angiotensin-converting enzyme were similar to those of nicardipine.
In contrast, L-NAME had opposite effects on lipid peroxidation, angiotensin-converting enzyme and NO.
CONCLUSION: The antihypertensive effect of Nigella sativa oil appears to be mediated by a reduction in cardiac
oxidative stress and angiotensin-converting enzyme activity, an increase in cardiac heme oxygenase-1 activity
and a prevention of plasma nitric oxide loss. Thus, Nigella sativa oil might be beneficial for controlling
hypertension.
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’ INTRODUCTION
Hypertension is defined as a persistent elevation of systolic
blood pressure of 140 mmHg or greater and/or diastolic blood
pressure of 90 mmHg or greater. Hypertension is a major risk
factor for cardiovascular, cerebrovascular and renal diseases (1).
Oxidative stress is important in the pathogenesis of
essential hypertension or in arterial damage related to
essential hypertension (2-3). This was shown by an elevation
of lipid peroxidation in hypertensive patients (2). The
increases in oxidative stress will reduce the bioavailability
of nitric oxide (NO), a potent vasodilator (3) and this
reduction contributes to the development of hypertension.
Many factors are involved in blood pressure control,
including angiotensin-converting enzyme (ACE), heme oxyge-
nase (HO-1) and the endothelial-derived relaxing factor (EDRF)
NO. ACE promotes the production of angiotensin II (Ang II)
from angiotensin I (Ang I), which has a direct vasoconstrictor
effect on the vessels that increase blood pressure. Ang II has
been reported to increase vascular superoxide anion production
via membrane NADPH oxidase activation, which will then lead
to an increase in lipid peroxidation, inflammation and vascular
injury (4-5). HO-1 protects against cardiovascular diseases such
as atherosclerosis and hypertension (6). The antihypertensive
effect of HO-1 is likely to be mediated by carbon monoxide
(CO). CO reduces peripheral resistance by directly dilating
blood vessels via the activation of guanylate cyclase (7). CO
exerts antihypertensive effects by stimulating the release of NO,
reducing sympathetic outflow and promoting sodium excretion
via the kidneys (6). Overexpression of the HO-1 gene reduces
the Ang II-mediated pressure response in rats (6). However,
HO-1 regulates blood pressure by reducing the activity of Ang II,
which helps to reduce vascular inflammation and protects
against vascular injuries (6). Cardiac-specific expression ofDOI: 10.6061/clinics/2015(11)07
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HO-1 was shown to protect against inflammation and oxidative
damage in healthy subjects (7). Treatment with heme-arginate,
an HO-1 inducer, protects the heart by reducing subendocardial
injury, interstitial fibrosis and cardiomyocyte hypertrophy, which
is believed to occur via a reduction in several inflammatory and
oxidative mediators (8).
The use of medicinal plants for the prevention of
cardiovascular diseases has been increasing recently. Nigella
sativa, which is also known as black cumin, has been shown
to possess blood pressure-lowering effects in both animals
and humans (9-13). It has been used for centuries for
medicinal and culinary purposes throughout the Middle
East, India and Northern Africa (11). The seed oil of N. sativa
was found to be rich in thymoquinone and polyphenols (13).
However, the exact mechanism of the blood pressure-
lowering effects of N. sativa remains uncertain. The antihyper-
tensive effects of N. sativa may involve several mechanisms.
El Tahir et al. (11) suggested that N. sativa likely reduces blood
pressure via a reduction in myocardial contractility and heart
rate and that N. sativa might activate muscarinic receptors on
blood vessels. However, Magyar et al. (14) suggested that
N. sativa might have calcium channel-blocking properties. To
the best of our knowledge, the effects ofN. sativa on ACE, HO-1,
NADPH oxidase and NO have not been thoroughly explored.
Therefore, the present study was designed to determine the
effects of N. sativa oil on ACE, HO-1 and cardiac redox status
(NADPH oxidase and malondialdehyde) in No-nitro-L-arginine
methyl ester (L-NAME)-treated rats. Nicardipine was used in the
study as a positive control because it has antioxidant effects and
calcium channel-blocking properties.
’ MATERIALS AND METHODS
Experimental study design
After a week of adaptation, twenty-four male Sprague-
Dawley rats (180-220 g) obtained from the Laboratory Animal
Resource Unit, Faculty of Medicine, Universiti Kebangsaan
Malaysia were divided into four experimental groups. One
group served as a control whereas the other three groups were
administered L-NAME intraperitoneally (25 mg/kg) (15).
Groups 3 and 4 were given both oral N. sativa oil (2.5 mg/kg)
(16) and oral nicardipine (3 mg/kg), respectively, (17) daily for
8 weeks concomitantly with L-NAME administration. After
8 weeks of treatment, the rats were sacrificed, and their hearts
were harvested. Systolic blood pressure was measured weekly
by a tail-cuff method (Powerlab, ADInstrument, NSW, Australia).
Blood was obtained at weeks 0 and 8 for the determination
of plasma nitric oxide. The rats were kept in polyethylene cages
in a well-ventilated room at 27o C with a QJ;12-hour light-dark
cycle and had free access to water and food throughout the
study. All animal management and handling procedures, in
addition to the study design, were approved by the university
ethical and research committee (Approval No.: 421-January-2012-
December-2013).
Measurement of blood pressure
A non-invasive method was used to measure systolic
blood pressure as described by Jaarin et al. (18) using
PowerLab data acquisition systems (ADInstruments, Castle
Hill, NSW, Australia). A monitoring cuff was placed on the
proximal tail to detect changes in blood flow that occurred
during occlusion or the release of the cuff. The rats were
placed in an approximately body-sized plastic container
prior to the blood pressure measurement. This step ensured
acclimation and a faster blood pressure measurement. The
animals were pre-warmed for 15 minutes to increase blood
flow to the tails. A minimum of 5 measurements were
recorded and the mean was used for analysis.
Heart malondialdehyde content measurement
Lipid peroxidation determined as malondialdehyde
(MDA) was measured in the cardiac samples following a
method by Ledwozyw et al. (19) with some modifications.
The protein content in the heart was estimated using an
established method (20).
Heart NADPH oxidase assay
NADPH oxidase activity measured as superoxide produc-
tion in the cardiac samples was based on a reduction of
ferricytochrome c in ferrocytochrome at pH 7.8 as described by
Mustapha et al. (21). The samples were homogenized in 0.25 M
sucrose (pH 7.8). The reaction mixture containing 250 mg/l
cytochrome c, 100 mM NADPH and 50 mg of protein samples
was incubated at 37o C for 120 min, either in the presence or
absence of diphenyleneiodonium (DPI, 100 mM). The absor-
bance of the reduction of cytochrome c was read at 550 nm.
Superoxide production was calculated from the difference
between the absorbance of the samples incubated with and
without DPI using an extinction coefficient of 21 mM-1cm-1.
ACE and HO-1 assays
ACE (USCN Life, West Lake, Wuhan, China) and HO-1
(Enzo Life Sciences, MI, USA) activities were analyzed in
cardiac samples using commercially available kits following
the manufacturer’s instructions. The colored end products of
these enzymes were measured by a microplate reader
(Molecular Devices, Sunnyvale, CA, USA) at 450 nm.
Nitric oxide
The production of NO was indirectly detected by measur-
ing the nitrite (NO2
-) metabolite content in the samples.
Plasma and cardiac NO content were estimated based on a
previously described method (22) using Griess reagent
(Sigma-Aldrich, St. Louis, MO, USA). Briefly, 50 mg of tissue
samples were incubated with the same volume of Griess
reagent in a microplate for 5 min in the dark at room
temperature. The colored end product was measured using a
microplate reader at 540 nm. Plasma NO was expressed as
the percentage difference between weeks 0 and 8.
Statistical analysis
The data are presented as the mean±SEM. The statistical
analyses were conducted using Statistical Product for Social
Science 16.0 software (SPSS, Inc., Chicago, IL). The normality
of the data was evaluated using a Kolmogorov–Smirnov test.
Differences between the groups for each parameter were
compared using a one-way analysis of variance (ANOVA)
with Tukey’s Honestly Significant Differences post-hoc test.
Statistical significance was defined as po0.05.
’ RESULTS
Effects on systolic blood pressure
There was a significant increase in systolic blood pressure
in the L-NAME-treated rats from week 2 to week 8 of the
study. Conversely, the treatment of the L-NAME-treated
hypertensive rats with N. sativa and nicardipine resulted in a
significantly lower blood pressure (Figure 1). The blood
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pressures of the control, N. sativa- and nicardipine-treated
groups were similar.
Effect on cardiac MDA
The L-NAME-treated group displayed a significant
increase in cardiac MDA content compared to the control.
L-NAME+nicardipine and L-NAME+Nigella sativa signifi-
cantly lowered the MDA content compared to the L-NAME
alone (po0.05) (Figure 2). There was no significant difference
in cardiac MDA content in the control, L-NAME+
nicardipine and L-NAME+Nigella sativa groups.
Effect on cardiac NADPH oxidase activity
A significant elevation of cardiac NADPH oxidase activity
was observed in the L-NAME group. The nicardipine- and
N. sativa-treated groups displayed lower enzyme activity. No
significant difference was noted among the control, nicardi-
pine- and N. sativa-treated groups (Figure 3).
Effect on cardiac ACE, HO-1 activities and
NO content
L-NAME administration increased cardiac ACE activity
compared to control, nicardipine and N. sativa treatments. In
contrast, enzyme activity was significantly reduced in the
nicardipine- and N. sativa-treated groups (po0.05) (Table 1).
No significant difference was observed in ACE activity
between these two groups. The HO-1 activity in cardiac
tissues was unaffected by L-NAME. However, the activity of
HO-1 was significantly higher in the N. sativa-treated group
than in the control (po0.005) and nicardipine (po0.05)
groups (Table 1). The NO content in the heart was unaffected
by either the treatment of L-NAME or the treatment of
N. sativa (Table 1).
Effect on plasma NO
There was a significant reduction in plasma NO levels in
the L-NAME and nicardipine-treated groups compared to
the control (po0.001). The NO level was significantly higher
in the N. sativa-treated group compared to the L-NAME and
nicardipine-treated groups (po0.001) (Figure 4).
’ DISCUSSION
In this study, we demonstrated that the intraperitoneal
administration of an NO synthase inhibitor (L-NAME) at
a dose of 25 mg/kg increased blood pressure in rats. This
finding was similar to previous studies, which reported
that L-NAME at a dose of 40-55 mg/kg per day increased
blood pressure (23-24). The blood pressure raising effect of
L-NAME in this study was not only associated with a
significant decrease in serum NO but also with an increase in
stress oxidative biomarkers, including MDA and NADPH
oxidase. These findings suggest that the blood pressure-
raising effects of L-NAME might not be purely attributed to
the inhibition of NO synthase but may involve oxidative
stress via the activation of NADPH oxidase expression. Our
results were consistent with those of another study, which
reported that L-NAME administration at a dose of 0.7 mg/ml
in drinking water for 2 weeks enhanced NADPH oxidase
expression in aortic tissue (25). Toba et al. (25) reported that
L-NAME administration increased oxidative stress, vascular
inflammation and ACE activity and expression. Our result
suggests that L-NAME may increase blood pressure via the
activation of the renin-angiotensin system. This finding was
in line with Zanchi et al. (23), who reported that L-NAME
might increase blood pressure via activation of the renin-
angiotensin system. In this study, L-NAME reduced NO
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Figure 1 - Systolic blood pressure in rats given N. sativa oil (NS) and concurrent administration of L-NAME. The data represent the
mean±SEM (n=6). *po0.01 versus control, #po0.05 versus L-NAME.
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levels in the plasma but not in the cardiac tissues. This
finding was contrasted with Bernatova et al. (24), who
reported that L-NAME reduced the activity of NO synthase
in the left ventricle. Moreover, Ndisang et al. (8) reported that
L-NAME-treated rats had increased cyclic guanosine and
pro-inflammatory chemokines and cytokines in the heart.
The reason for this finding was not clear. We postulated that
the negative effect of L-NAME on cardiac NO levels may be
a result of the lower dose of L-NAME used in this study,
which was 25 mg/kg/day, whereas Bernatova et al. (24)
used a higher dose of L-NAME (40 mg/kg/day).
The administration of N. sativa oil a dose of 2.5 mg/kg for
8 weeks attenuated the systolic blood pressure increase in the
rats that were co-treated with L-NAME. The effect of the oil
on blood pressure in this study was in agreement with other
studies (9-13). The reduction in systolic blood pressure with
N. sativa in this study was accompanied by significant
reductions in MDA, ACE and NADPH oxidase activities and
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Figure 2 - Effect of N. sativa oil on heart lipid peroxidation product in rats administered L-NAME for 8 weeks. The bars represent the
mean±SEM (n=6). *po0.01 versus control, # po0.05 versus L-NAME.
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Figure 3 - Effects of N. sativa oil on NADPH oxidase enzyme activity in L-NAME administered rats. The bars represent the mean±SEM
(n=6). *po0.005 versus control, #po0.05 versus L-NAME.
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by an increase in HO-1 activity in cardiac tissue, in addition
to an increase in plasma NO. Khattab and Nagi (12) also
reported that thymoquinone at a dose of 0.5 mg/kg/day and
1 mg/kg/day orally prevented L-NAME-induced hyperten-
sion and renal damage, most likely via an antioxidant effect.
Reductions in L-NAME-induced MDA content and NADPH
oxidase activity by the N. sativa oil in this study indicate that
the oil has an antioxidant effect and may contribute to blood
pressure reduction. The antioxidant effects of N. sativa have
been reported previously (11-13). This finding concurs with
Sayed et al. (13) and the Khatab and Nagi (12) studies, which
suggested that the antioxidant effect of N. sativa contributed
towards its antihypertensive effect. The seed oil that contains
thymoquinone, dithymoquinone and thymol might contribute
to this effect (10,13). Thymol acts as a singlet oxygen quencher
whereas thymoquinone and dithymoquinone have superoxide
dismutase (SOD)-like activity and also act as free radical
scavengers (27-29). Oxidative stress causes endothelial dysfunc-
tion, leading to a reduction in the release or production of NO
(30-32), the proliferation of vascular smooth muscle cells and
collagen deposition, which causes a thickening of the tunica
media, and a narrowing of the vascular lumen (28), which in
turn impairs vasodilation (30-32). Apart from its antioxidant
properties, the blood pressure-lowering effect of N. sativa may
be attributed to its diuretic properties (33), its anti-inflammatory
effect (34) or its reno-protective effect (35).
The activation of HO-1 plays an important role in reducing
blood pressure by reducing Ang II-induced inflammation and
NADPH oxidase-mediated oxidative stress via the production
of anion superoxide (4-6). The antihypertensive effect of HO-1
is attributable to its production of CO, which also has a
vasodilator effect (6). In our study, cardiac HO-1 activity was
significantly increased in rats that were treated with L-NAME
and N. sativa. The effect of thymoquinone on the overexpression
of HO-1 expression was also reported by Kundu et al. (36).
ACE converts Ang I to Ang II. The reduction of ACE
activity leads to a reduction in blood pressure because of the
reduction in Ang II synthesis. Ang II acts as a potent
vasoconstrictor. Ang II exacerbates oxidative stress by
increasing the production of superoxide (4-5). Increased
ACE activity and oxidative stress was observed in hyperten-
sive animals (23-25). Increased plasma Ang II availability
was reported in L-NAME-treated rats because of endothelial
NO synthase (eNOS) inhibition (25). In the current study,
N. sativa oil reduced cardiac ACE activity in rats receiving
L-NAME. This result suggests that the antioxidant properties
of N. sativa oil contributed to the reduction of the enzyme
activity. We are unsure of how the reduction in cardiac ACE
Table 1 - Cardiac angiotensin-converting enzyme, heme oxygenase activities and nitric oxide level.
ACE (pg/g) HO (ng/g) Nitric oxide (lmol/g)
Control 520.27 ± 42.59 8.66 ± 0.45 0.129 ± 0.004
L-NAME 637.40 ± 14.95* 11.69 ± 0.94 0.106 ± 0.011
L-NAME+Nicardipine 483.07 ± 31.29# 9.79 ± 0.84 0.132 ± 0.010
L-NAME+Nigella 464.07 ± 31.29# 15.48 ± 2.02*y 0.098 ± 0.008
* versus control (po0.05), # versus L-NAME (po0.05), y versus L-NAME+Nicardipine (po0.05).
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Figure 4 - Percentage change of plasma NO (weeks 0 and 8) in rats administered L-NAME and N. sativa oil for 8 weeks. The bars
represent the mean±SEM (n=6). *po0.001 versus control, #po0.001 versus L-NAME, ypo0.001 versus nicardipine-treated group.
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reduced blood pressure because our study did not measure
serum ACE and aldosterone levels. Further study of serum
ACE and aldosterone must be performed in the future.
However, a previous study by Zeggwagh et al. (37) demon-
strated that N. sativa aqueous extract had no effect on plasma
ACE activity in spontaneously hypertensive rats.
EDRF, better known as NO, causes vasodilation, which
subsequently reduces total peripheral resistance and hence
reduces blood pressure. The inhibition of eNOS reduces NO
production, whereas eNOS stimulation increases NO produc-
tion. Our study showed that treatment with N. sativa
prevented the loss of plasma NO caused by L-NAME. The
mechanism on how N. sativa reversed the reduction in NO
levels in spite of L-NAME was unclear. We postulated that the
effect is most likely attributable to the high antioxidant
content of N. sativa, which helps prevent oxidative stress,
vascular inflammation and dysfunction induced by L-NAME.
A similar antioxidant effect on NO was reported by Nurul-
Iman et al. (38).
The effect of N. sativa in this study was comparable to that
of nicardipine, which is a short-acting calcium antagonist. We
chose nicardipine for this study because it has antioxidant
effects and N. sativa was reported to possess calcium channel-
blocking properties (14). The nicardipine-induced reduction of
blood pressure in this study was associated with a reduction
in MDA and NADPH oxidase, which indicated that nicardi-
pine has antioxidant properties. The antioxidant effect of a
calcium antagonist has been previously reported (39). In this
study, similar to N. sativa, nicardipine reduced cardiac ACE.
The effect of nicardipine on ACE in this study was in
accordance with Kataoka et al. (40), who reported that a
calcium channel blocker had an effect on the renin-angiotensin
system and hypothesized that the anti-inflammatory and
antioxidant effects of calcium channel blockers might be a
result of the inhibition of the local renin-angiotensin system.
The effect of a calcium antagonist on ACE was further
supported by Toba et al. (25); they reported that amlodipine
prevented the increase in ACE in L-NAME treated rats.
However, in this study, nicardipine was not able to inhibit the
loss of NO induced by L-NAME treatment. The effect of
nicardipine in this study differed from the results of a few
other studies that demonstrated that the long-acting calcium
antagonists amlodipine and felodipine increased endothelial
NO synthase (eNOS) activity and gene expression, respec-
tively and hence increased NO (25). The reason for the
discrepancy between our results and those of the other two
studies was unclear. We postulated that short- and long-acting
calcium channel blockers might have different effects on NO.
In this study, we used nicardipine, which belongs to a short-
acting dihydropyridine group of calcium antagonists, whereas
the other study (25) used a long-acting drug. Further study
will be necessary to clarify this discrepancy. Unlike N. sativa,
nicardipine had no effect on HO-1. In conclusion, N. sativa oil
at a dose of 2.5 mg/kg attenuates the L-NAME-induced
increase in blood pressure and was associated with a
reduction in cardiac redox status and angiotensin-converting
enzyme activity and an increase in HO-1 activity. N. sativa oil
also prevented plasma NO loss. Notably, the blood pressure-
lowering effect was comparable to that of nicardipine.
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